| John Bradfield Heinrich, MD | |
|
12222 N Central Expy Ste 130, Dallas, TX 75243-3758 | |
| (214) 265-3260 | |
| (214) 265-3261 |
| Full Name | John Bradfield Heinrich |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 21 Years |
| Location | 12222 N Central Expy Ste 130, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053526533 | NPI | - | NPPES |
| 204220202 | Medicaid | TX | |
| 204220203 | Medicaid | TX | |
| 8AD834 | Other | TX | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | M4142 (Texas) | Primary |
| 207X00000X | Orthopaedic Surgery | 01064754A (Indiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Home Health Professionals Dallas | Dallas, TX | Home health agency |
| Baylor Scott And White Medical Center Uptown | Dallas, TX | Hospital |
| Methodist Hospital For Surgery | Addison, TX | Hospital |
| Entity Name | Healthtexas Provider Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760488936 PECOS PAC ID: 1355254210 Enrollment ID: O20040727001187 |
News Archive
The committee's decision stands in stark contrast to the recent verdict by the U.S. Food and Drug Administration, which is wary of Avastin's benefits for breast-cancer patients.
A new state-of-the-art research facility dedicated to helping produce modified cells for treatment of cancer and other diseases recently opened at the Siteman Cancer Center.
It will soon be possible for anyone over 60 to predict their individual risk of bone fracture with the aid of a simple web-based tool, developed by the Sydney-based Garvan Institute of Medical Research.
Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
› Verified 7 days ago
| Entity Name | Hilltop Orthopedics And Sports |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053078824 PECOS PAC ID: 4789074303 Enrollment ID: O20220309000093 |
News Archive
The committee's decision stands in stark contrast to the recent verdict by the U.S. Food and Drug Administration, which is wary of Avastin's benefits for breast-cancer patients.
A new state-of-the-art research facility dedicated to helping produce modified cells for treatment of cancer and other diseases recently opened at the Siteman Cancer Center.
It will soon be possible for anyone over 60 to predict their individual risk of bone fracture with the aid of a simple web-based tool, developed by the Sydney-based Garvan Institute of Medical Research.
Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Bradfield Heinrich, MD Po Box 676928, Dallas, TX 75267-6928 Ph: (214) 265-3260 | John Bradfield Heinrich, MD 12222 N Central Expy Ste 130, Dallas, TX 75243-3758 Ph: (214) 265-3260 |
News Archive
The committee's decision stands in stark contrast to the recent verdict by the U.S. Food and Drug Administration, which is wary of Avastin's benefits for breast-cancer patients.
A new state-of-the-art research facility dedicated to helping produce modified cells for treatment of cancer and other diseases recently opened at the Siteman Cancer Center.
It will soon be possible for anyone over 60 to predict their individual risk of bone fracture with the aid of a simple web-based tool, developed by the Sydney-based Garvan Institute of Medical Research.
Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).
Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
› Verified 7 days ago
Dr. Christopher Michael Sakowski, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7115 Greenville Ave Ste 310, Dallas, TX 75231 Phone: 214-265-3200 Fax: 214-265-3285 | |
Sumant G Krishnan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9301 N Central Expy, Suite 400, Dallas, TX 75231 Phone: 214-220-2468 Fax: 214-397-1555 | |
Jorge Casas, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 12222 N Central Expy, Suite 210, Dallas, TX 75243 Phone: 214-615-1949 Fax: 214-615-1949 | |
Nathan Bruck, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 411 N Washington Ave Ste 7000, Dallas, TX 75246 Phone: 214-823-7090 Fax: 214-823-1644 | |
Dr. Michael Wheeler, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln Ste 130, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-750-8504 | |
Dr. Richard S Levy, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 6901 Snider Plz, Ste 200, Dallas, TX 75205 Phone: 214-369-7733 Fax: 214-360-9604 | |
Dr. Robert Russell Scheinberg, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln, Ste 130, Lb 11, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 |